| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,203 |
14,833 |
$1.49M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
16,467 |
16,022 |
$1.45M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,234 |
5,188 |
$507K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,070 |
3,066 |
$266K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
422 |
417 |
$36K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,440 |
3,328 |
$13K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
143 |
143 |
$12K |
| 87400 |
|
4,440 |
2,804 |
$14.13 |
| 81003 |
|
714 |
711 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,004 |
2,981 |
$0.00 |
| 81002 |
|
189 |
187 |
$0.00 |
| 69209 |
|
14 |
13 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
169 |
169 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
321 |
317 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,745 |
4,664 |
$0.00 |
| 87807 |
|
965 |
939 |
$0.00 |
| 87428 |
|
509 |
508 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
18 |
16 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
92 |
89 |
$0.00 |